ConductScience.org, home

Paper33192068

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema.

Giarmoukakis AK and 6 others. Ther Clin Risk Manag, 2020. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema. Papers, record 33192068. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33192068

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema.
PubMed
Journal
Ther Clin Risk Manag
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.62
iCite
Revised in PubMed
2022-04-18
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Giarmoukakis AKAthanassios K
2Blazaki SVStyliani V
3Bontzos GCGeorgios C
4Plaka ADArgyro D
5Seliniotakis KNKonstantinos N
6Ioannidi LDLarissa D
7Tsilimbaris MKMiltiadis Khttps://orcid.org/0000-0002-0130-1150

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128268098Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.Ophthalmology2017https://conductscience.org/library/papers/28268098PubMed
217720067In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.J Cataract Refract Surg2007https://conductscience.org/library/papers/17720067PubMed
322927737Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy.Clin Ophthalmol2012https://conductscience.org/library/papers/22927737PubMed
414709300Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolac.J Cataract Refract Surg2003https://conductscience.org/library/papers/14709300PubMed
528351047Postsurgical Cystoid Macular Edema.Dev Ophthalmol2017https://conductscience.org/library/papers/28351047PubMed
629269999Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives.Clin Ophthalmol2017https://conductscience.org/library/papers/29269999PubMed
718988178Pseudophakic macular edema and oral acetazolamide: an optical coherence tomography measurable, dose-related response.Eur J Ophthalmol2008https://conductscience.org/library/papers/18988178PubMed
820175270NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema.Retina2010https://conductscience.org/library/papers/20175270PubMed
922440164Evaluation of cystoid macular edema using optical coherence tomography and fundus fluorescein angiography after uncomplicated phacoemulsification surgery.Curr Eye Res2012https://conductscience.org/library/papers/22440164PubMed
1025285465Reliability of intravitreal nepafenac in rabbits.J Ocul Pharmacol Ther2015https://conductscience.org/library/papers/25285465PubMed
11655537Route of absorption of drug and ointment after application to the eye.Ann Ophthalmol1978https://conductscience.org/library/papers/655537PubMed
1220703048Postsurgical cystoid macular edema.Dev Ophthalmol2010https://conductscience.org/library/papers/20703048PubMed
1319639332Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy.Graefes Arch Clin Exp Ophthalmol2009https://conductscience.org/library/papers/19639332PubMed
145964923Fluorescein studies of patients with macular edema and papilledema following cataract extraction.Trans Am Ophthalmol Soc1966https://conductscience.org/library/papers/5964923PubMed
1527388251
Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy.
Br J Ophthalmol2017https://conductscience.org/library/papers/27388251PubMed
16785652Cystoid maculopathy.Surv Ophthalmol1976https://conductscience.org/library/papers/785652PubMed
1726681390Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes.Ophthalmology2016https://conductscience.org/library/papers/26681390PubMed
1826474497Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.Exp Eye Res2016https://conductscience.org/library/papers/26474497PubMed
1910189253Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye.J Pharm Sci1998https://conductscience.org/library/papers/10189253PubMed
2018001248Cystoid and diabetic macular edema treated with nepafenac 0.1%.J Ocul Pharmacol Ther2007https://conductscience.org/library/papers/18001248PubMed

See all 23 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42271301Comparison of topical nepafenac 0.1% and 0.3% for the treatment of pseudophakic cystoid macular edema following cataract surgery.BMC Ophthalmol2026https://conductscience.org/library/papers/42271301PubMed
41209449A Case of Corneal Melting Associated with Topical Diclofenac After Phacovitrectomy for Macular Pucker in a Patient with Rheumatoid Arthritis.Int Med Case Rep J2025https://conductscience.org/library/papers/41209449PubMed
41003131Irvine-Gass Syndrome Personalized Treatment Outcomes: A Retrospective Single-Center Cohort Study.J Pers Med2025https://conductscience.org/library/papers/41003131PubMed
38274400Navigated yellow subthreshold micropulse laser for refractory cystoid macular edema following rhegmatogenous retinal detachment surgery.Am J Ophthalmol Case Rep2024https://conductscience.org/library/papers/38274400PubMed
34640393Current Management Options in Irvine-Gass Syndrome: A Systemized Review.J Clin Med2021https://conductscience.org/library/papers/34640393PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33192068

GET https://conductscience.org/api/papers/v1/33192068/references?page=2